<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565902</url>
  </required_header>
  <id_info>
    <org_study_id>CBAF312A2122</org_study_id>
    <secondary_id>2012-000562-37</secondary_id>
    <nct_id>NCT01565902</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of BAF312 in Patients With Hepatic Impairment</brief_title>
  <official_title>A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the pharmacokinetics of BAF312 in patients with mild, moderate
      and severe hepatic impairment compared to healthy control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</time_frame>
    <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</time_frame>
    <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose</time_frame>
    <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events, Serious Adverse Events and Death Adverse Events (Frequency of Adverse Events, Serious Adverse Events, and Notable Laboratory Abnormalities) of of BAF312 After a Single Dose of BAF312</measure>
    <time_frame>Day -1 to 22</time_frame>
    <description>Physical examination, vital signs, body temperature, standard safety laboratory evaluations (hematology, clinical chemistry, coagulation, Hepatitis B and C and HIV serology, α-fetoprotein [in hepatically impaired subjects only], pregnancy test, alcohol and drug screen), standard 12-lead electrocardiogram , cardiac monitoring, 24-h Holter ECG, suicidality assessment (C-SSRS), (serious) adverse event monitoring.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mild hepatically impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatically impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe hepatically impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF312</intervention_name>
    <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
    <arm_group_label>Mild hepatically impaired</arm_group_label>
    <arm_group_label>Moderate hepatically impaired</arm_group_label>
    <arm_group_label>Severe hepatically impaired</arm_group_label>
    <arm_group_label>Matched healthy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects:

          -  Male and female Caucasian subjects 18 to 70 years of age

          -  At least 50 kg and body mass index (BMI) within 18-35 kg/m2.

          -  CYP2C9 wild-type (CYP2C9*1 homozygous carriers)

        Hepatic impairment:

        - Subjects must have either mild, moderate or severe hepatic impairment

        Exclusion Criteria:

        All subjects

          -  Hepatic impairment due to non-liver disease.

          -  Use of other investigational drugs within certain timelines

          -  Donation or loss of 400 mL or more of blood or plasma within eight (8) weeks prior to
             initial dosing

          -  History of cardiac rhythm abnormalities or cardiac rhythm abnormalities identified in
             the 24-h Holter ECG recording including episodes of bradycardia (HR &lt; 50 bpm) during
             waking hours and/or arrhythmic episodes; subjects with history or presence of
             ventricular rhythm disturbances (ventricular extra-systoles &gt;100/24h, or higher
             grade), or supraventricular arrhythmias (other than occasional supraventricular
             ectopic beats with a maximum of 5 subsequent ectopic beats per event) or subjects with
             conduction disturbances (higher than AV-block grade 1) or bradycardia or tachycardia.

          -  History of cardiac catheter ablation.

          -  Women of child-bearing potential

          -  History of malignancy of any organ system

          -  Recent and/or recurrent history of acute or chronic bronchospastic disease (including
             asthma and chronic obstructive pulmonary disease)

          -  History or presence of symptomatic postural hypotension or syncope.

          -  Total WBC or lymphocyte counts which falls outside the 1.5-fold local laboratory
             normal range or platelet count &lt; 30,000/μL at screening or baseline.

          -  Clinically significant infection or recent vaccination with live-attenuated vaccines.

          -  History or presence of hepatitis B or C and/or positive Hepatitis B surface antigen
             (HBsAg) or Hepatitis C test result at screening.

          -  History or presence of coronary heart disease (stable or unstable), myocardial
             infarction, myocarditis, cardiomyopathy, heart failure NYHA II - IV.

        Hepatic impairment:

          -  History or presence of any non-controlled and clinically significant disease that
             could affect the study outcome or that would place the patient at undue risk.

          -  Any surgical or medical condition other than hepatic impairment which might
             significantly alter the absorption, distribution, metabolism, or excretion of drugs,
             or which may jeopardize the safety of the study subject in case of participation in
             the study.

          -  Treatment with certain drugs

        Healthy subjects:

          -  History or presence of any clinically significant disease of any major system organ
             class including (but not limited to) cardiovascular, metabolic, renal, neurological or
             psychiatric diseases.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of drugs, drugs, or which may jeopardize the
             subject in case of participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115419</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.dustri.com/nc/article-response-page.html?artId=14609&amp;doi=10.5414%2FCP202588</url>
    <description>Publication from the International Journal of Clinical Pharmacology and Therapeutics</description>
  </link>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=13203</url>
    <description>Study results from Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <results_first_submitted>December 12, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BAF312</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Up to forty-eight subjects were planned to be enrolled in four groups. A total of 40 subjects were enrolled and completed the study. All subjects were included in the safety and PK analysis. However, only 38 subjects were included for primary PK analysis based on matched pair analysis</recruitment_details>
      <pre_assignment_details>To potentially reduce the number of healthy subjects exposed to BAF312, study allowed for multiple matching of subjects with hepatic impairment to healthy subjects. During the study, 2 healthy subjects were not matched to any of the subjects with hepatic impairment due to a retrospective identification of a better matching partner</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mild Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="P2">
          <title>Moderate Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="P3">
          <title>Severe Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="P4">
          <title>Matched Healthy Subjects</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mild Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="B2">
          <title>Moderate Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="B3">
          <title>Severe Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="B4">
          <title>Matched Healthy Subjects</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="6.20"/>
                    <measurement group_id="B2" value="47.8" spread="6.30"/>
                    <measurement group_id="B3" value="51.8" spread="3.41"/>
                    <measurement group_id="B4" value="50.1" spread="5.50"/>
                    <measurement group_id="B5" value="50.7" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)</title>
        <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</description>
        <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</time_frame>
        <population>The PK analysis set consists of all completed subjects with quantifiable pharmacokinetic (PK) measurements. To reduce the number of healthy subjects exposed to BAF312, study allowed matching of subjects with hepatic impairment to healthy subjects. A healthy subject served as matching partner for up to 3 subjects with hepatic impairment</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O3">
            <title>Severe Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O4">
            <title>Matched Healthy Subjects – Mild</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O5">
            <title>Matched Healthy Subjects - Moderate</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O6">
            <title>Matched Healthy Subjects - Severe</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)</title>
          <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</description>
          <population>The PK analysis set consists of all completed subjects with quantifiable pharmacokinetic (PK) measurements. To reduce the number of healthy subjects exposed to BAF312, study allowed matching of subjects with hepatic impairment to healthy subjects. A healthy subject served as matching partner for up to 3 subjects with hepatic impairment</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" spread="24.5"/>
                    <measurement group_id="O2" value="53.9" spread="7.57"/>
                    <measurement group_id="O3" value="73.7" spread="25.4"/>
                    <measurement group_id="O4" value="64.2" spread="20.8"/>
                    <measurement group_id="O5" value="63.2" spread="18.6"/>
                    <measurement group_id="O6" value="64.9" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)</title>
        <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</description>
        <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</time_frame>
        <population>The PK analysis set consists of all completed subjects with quantifiable pharmacokinetic (PK) measurements. To reduce the number of healthy subjects exposed to BAF312, study allowed matching of subjects with hepatic impairment to healthy subjects. A healthy subject served as matching partner for up to 3 subjects with hepatic impairment</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O3">
            <title>Severe Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O4">
            <title>Matched Healthy Subjects – Mild</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O5">
            <title>Matched Healthy Subjects - Moderate</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O6">
            <title>Matched Healthy Subjects - Severe</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)</title>
          <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose.</description>
          <population>The PK analysis set consists of all completed subjects with quantifiable pharmacokinetic (PK) measurements. To reduce the number of healthy subjects exposed to BAF312, study allowed matching of subjects with hepatic impairment to healthy subjects. A healthy subject served as matching partner for up to 3 subjects with hepatic impairment</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="24.4"/>
                    <measurement group_id="O2" value="52.3" spread="7.51"/>
                    <measurement group_id="O3" value="71.6" spread="24.5"/>
                    <measurement group_id="O4" value="62.5" spread="20.9"/>
                    <measurement group_id="O5" value="61.7" spread="18.7"/>
                    <measurement group_id="O6" value="63.4" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax)</title>
        <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose</description>
        <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose</time_frame>
        <population>The PK analysis set consists of all completed subjects with quantifiable pharmacokinetic (PK) measurements. To reduce the number of healthy subjects exposed to BAF312, study allowed matching of subjects with hepatic impairment to healthy subjects. A healthy subject served as matching partner for up to 3 subjects with hepatic impairment</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O3">
            <title>Severe Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O4">
            <title>Matched Healthy Subjects – Mild</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O5">
            <title>Matched Healthy Subjects - Moderate</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O6">
            <title>Matched Healthy Subjects - Severe</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax)</title>
          <description>The pharmacokinetics of BAF312 were studied in plasma up to 504 hours post-dose at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, 216, 312, 408 and 504 hours post dose</description>
          <population>The PK analysis set consists of all completed subjects with quantifiable pharmacokinetic (PK) measurements. To reduce the number of healthy subjects exposed to BAF312, study allowed matching of subjects with hepatic impairment to healthy subjects. A healthy subject served as matching partner for up to 3 subjects with hepatic impairment</population>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.532"/>
                    <measurement group_id="O2" value="1.54" spread="0.191"/>
                    <measurement group_id="O3" value="1.58" spread="0.304"/>
                    <measurement group_id="O4" value="1.74" spread="0.439"/>
                    <measurement group_id="O5" value="1.80" spread="0.417"/>
                    <measurement group_id="O6" value="1.94" spread="0.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events, Serious Adverse Events and Death Adverse Events (Frequency of Adverse Events, Serious Adverse Events, and Notable Laboratory Abnormalities) of of BAF312 After a Single Dose of BAF312</title>
        <description>Physical examination, vital signs, body temperature, standard safety laboratory evaluations (hematology, clinical chemistry, coagulation, Hepatitis B and C and HIV serology, α-fetoprotein [in hepatically impaired subjects only], pregnancy test, alcohol and drug screen), standard 12-lead electrocardiogram , cardiac monitoring, 24-h Holter ECG, suicidality assessment (C-SSRS), (serious) adverse event monitoring.</description>
        <time_frame>Day -1 to 22</time_frame>
        <population>The safety analysis set consists of all subjects that received study drug and with no protocol deviations with relevant impact on safety.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O3">
            <title>Severe Hepatically Impaired</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
          <group group_id="O4">
            <title>Matched Healthy Subjects</title>
            <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events, Serious Adverse Events and Death Adverse Events (Frequency of Adverse Events, Serious Adverse Events, and Notable Laboratory Abnormalities) of of BAF312 After a Single Dose of BAF312</title>
          <description>Physical examination, vital signs, body temperature, standard safety laboratory evaluations (hematology, clinical chemistry, coagulation, Hepatitis B and C and HIV serology, α-fetoprotein [in hepatically impaired subjects only], pregnancy test, alcohol and drug screen), standard 12-lead electrocardiogram , cardiac monitoring, 24-h Holter ECG, suicidality assessment (C-SSRS), (serious) adverse event monitoring.</description>
          <population>The safety analysis set consists of all subjects that received study drug and with no protocol deviations with relevant impact on safety.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Moderate Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="E2">
          <title>Severe Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="E3">
          <title>Matched Healthy Subjects</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
        <group group_id="E4">
          <title>Mild Hepatically Impaired</title>
          <description>Treatment with a single oral dose of 0.25 mg BAF312</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

